Wall Street Zen Downgrades Anixa Biosciences (NASDAQ:ANIX) to Sell

Anixa Biosciences (NASDAQ:ANIX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other equities analysts have also commented on the stock. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, February 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Finally, Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

Anixa Biosciences Price Performance

Shares of NASDAQ:ANIX opened at $2.96 on Friday. The stock has a market capitalization of $98.80 million, a P/E ratio of -8.46 and a beta of 0.53. The business has a 50-day moving average of $3.48 and a two-hundred day moving average of $3.58. Anixa Biosciences has a fifty-two week low of $2.33 and a fifty-two week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Monday, January 12th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). As a group, research analysts expect that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In related news, Director Arnold M. Baskies acquired 10,000 shares of the stock in a transaction dated Wednesday, January 28th. The shares were acquired at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the purchase, the director owned 135,000 shares in the company, valued at approximately $410,400. The trade was a 8.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Large investors have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new stake in Anixa Biosciences in the 2nd quarter worth $39,000. NewEdge Advisors LLC acquired a new position in shares of Anixa Biosciences during the second quarter valued at about $33,000. Jane Street Group LLC lifted its stake in shares of Anixa Biosciences by 37.2% in the second quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock valued at $138,000 after buying an additional 11,340 shares during the period. Benjamin Edwards Inc. acquired a new stake in Anixa Biosciences during the second quarter worth about $37,000. Finally, World Investment Advisors acquired a new stake in Anixa Biosciences during the third quarter worth about $48,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.